智通财经APP获悉，药明康德(603259.SH/02359)的股东回报机制正迈向新阶段。继2025年首次实施中期分红后，公司有望在2026年延续这一举措，实现连续第二年中期分红。结合年度分红计划，预计2026年现金分红总额将突破57亿元，刷新历史纪录。这意味着，“中期分红”正从一次性的特别举措，转变为公司常态化、可预期的回报机制。
常态化分红的底气，源于持续超预期的业绩增长。2025年业绩公告显示，公司全年营收达454.56亿元，归母净利润同比激增102.65%。强劲的盈利能力与健康的现金流，为持续高额分红提供了坚实基础。上市七年来，药明康德累计通过分红与回购回馈股东超200亿元，占同期净利润比例超40%。
分析指出，“中期分红常态化”传递出三重信号：一是管理层对经营现金流和全年盈利前景信心十足；二是“年度+中期”的双次分红节奏提升了资金效率，增强了投资吸引力；三是深化了“与股东共享发展成果”的经营理念。在追求确定性的市场环境下，药明康德正通过“业绩高增长+股东高回报”的双优表现，持续巩固其核心资产地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.